MedTrace Logo

Evaluation of the Million Hearts CVD Risk Reduction Model

NCT04047147 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 210000

Last updated 2019-08-06

No results posted yet for this study

Summary

The Million Hearts Cardiovascular Disease (CVD) Risk Reduction Model, run by the Centers for Medicare \& Medicaid Services (CMS), seeks to improve cardiovascular care by providing incentives and supports for health care practitioners to engage in patient CVD risk calculation and population-level CVD risk management. CMS enrolled organizations throughout the United States, randomly assigning half to the intervention and half to a control group. This study is an evaluation of the model and will assess the model impacts on patient outcomes, changes in CVD care processes, and implementation challenges and successes.

Conditions

Interventions

OTHER

Enrollment in the Million Hearts CVD Risk Reduction Model

The intervention is at a provider organization level and all eligible beneficiaries enrolled by participants will be considered exposed. Intervention organizations receive payments to: * Risk stratify eligible Medicare FFS beneficiaries * Provide CVD care management to high-risk beneficiaries * Collect and report clinical data to CMS via the Million Hearts Data Registry and participate in learning system activities Participating organizations receive payments for each eligible beneficiary they risk stratify. In model year 1, the organizations receive a fixed payment per beneficiary per month to provide cardiovascular management. In model years 2-5, the organizations receive a risk reduction payment that is scaled based on reductions in 10-year predicted risk scores among their cohort of high-risk beneficiaries.

OTHER

Enrollment in control provider organizations

Control organizations receive payments to collect and report clinical data on their eligible Medicare FFS beneficiaries, but are not asked to calculate CVD risk scores or otherwise change their clinical care.

Sponsors & Collaborators

Eligibility

Min Age
40 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-03
Primary Completion
2021-12-31
Completion
2022-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04047147 on ClinicalTrials.gov